user: GUEST
width: 600


MyHits has reached its end of life and no longer provides data or services. Thank you for your support and trust for more than 23 years!
However, the webserver will remain online in its present form at least until end of March 2025.
To ensure the future of MyHits, we would be happy if a person or community would take over the resource or parts of it. Interested? Please contact us (myhits [at] sib.swiss).

Pagni M, Ioannidis V, Cerutti L, Zahn-Zabal M, Jongeneel CV, Hau J, Martin O, Kuznetsov D, Falquet L.
MyHits: improvements to an interactive resource for analyzing protein sequences.
Nucleic Acids Res. 2007 Jul; 35(Web Server issue):W433-7

DescriptionRecName: Full=NEDD4 family-interacting protein 2; AltName: Full=NEDD4 WW domain-binding protein 5A; AltName: Full=Putative MAPK-activating protein PM04/PM05/PM06/PM07; AltName: Full=Putative NF-kappa-B-activating protein 413;
MyHits logo
MyHits synonymsNFIP2_HUMAN , Q9NV92 , Q7Z2H3 , Q7Z428 , Q8TAR3 , Q9ULQ5 , A7E386C12886321E
match map segment
 
Legends: 1, SITE Not phosphorylated by SRC; 2, Phosphotyrosine; by SRC; dependent on Y- 167. {ECO:0000269|PubMed:20534535}; 3, Phosphotyrosine; by SRC. {ECO:0000269|PubMed:20534535}; 4, VARIANT P -> S (in dbSNP:rs55887763); 5, VARIANT A -> V (in dbSNP:rs11549502). {ECO:0000269|PubMed:10574461, ECO:0000269|PubMed:12761501, ECO:0000269|PubMed:15489334}; 6, MUTAGEN Y->F: Loss of NDFIP2 phosphorylation by SRC. {ECO:0000269|PubMed:20534535}; 7, TRANSMEM Helical. {ECO:0000255}; 8, TOPO_DOM Extracellular. {ECO:0000255}; 9, TOPO_DOM Cytoplasmic. {ECO:0000255}; 10, REGION Interaction with NEDD4. {ECO:0000250}; 11, MOTIF WW-binding 1; 12, MOTIF WW-binding 2; 13, MOTIF WW-binding 3; 14, MUTAGEN PY->AG: Loss of E3 ubiquitin-protein ligase activation; when associated with 175-P--G-177 AND 184-P--G-186. Greatly decreases NEDD4-binding; when associated with 175-P--G-177 and 184-P--G-186. No effect on PTEN-binding; when associated with 175-P--G-177 AND 184-P--G-186; 15, MUTAGEN PY->AG: Loss of E3 ubiquitin-protein ligase activation; when associated with 149-P--G-151 AND 184-P--G-186. Greatly decreases NEDD4-binding; when associated with 149-P-G-151 AND 184-P--G-186. No effect on PTEN-binding; when associated with 149-P--G-151 AND 184-P--G-186; 16, MUTAGEN TY->AG: Loss of E3 ubiquitin-protein ligase activation; when associated with 149-P--G-151 AND 175-P--G-177. Greatly decreases NEDD4-binding; when associated with 149-P--G-151 AND 175-P--G-177. No effect on PTEN-binding; when associated with 149-P--G-151 AND 175-P--G-177.
ID   NFIP2_HUMAN             Reviewed;         336 AA.
AC   Q9NV92; Q7Z2H3; Q7Z428; Q8TAR3; Q9ULQ5;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   30-AUG-2005, sequence version 2.
DT   02-NOV-2016, entry version 124.
DE   RecName: Full=NEDD4 family-interacting protein 2;
DE   AltName: Full=NEDD4 WW domain-binding protein 5A;
DE   AltName: Full=Putative MAPK-activating protein PM04/PM05/PM06/PM07;
DE   AltName: Full=Putative NF-kappa-B-activating protein 413;
GN   Name=NDFIP2; Synonyms=KIAA1165, N4WBP5A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   INDUCTION, AND INTERACTION WITH NEDD4.
RC   TISSUE=T-cell;
RX   PubMed=12796489; DOI=10.1074/jbc.M304723200;
RA   Cristillo A.D., Nie L., Macri M.J., Bierer B.E.;
RT   "Cloning and characterization of N4WBP5A, an inducible, cyclosporine-
RT   sensitive, Nedd4-binding protein in human T lymphocytes.";
RL   J. Biol. Chem. 278:34587-34597(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], FUNCTION, AND VARIANT VAL-136.
RC   TISSUE=Lung fibroblast;
RX   PubMed=12761501; DOI=10.1038/sj.onc.1206406;
RA   Matsuda A., Suzuki Y., Honda G., Muramatsu S., Matsuzaki O.,
RA   Nagano Y., Doi T., Shimotohno K., Harada T., Nishida E., Hayashi H.,
RA   Sugano S.;
RT   "Large-scale identification and characterization of human genes that
RT   activate NF-kappaB and MAPK signaling pathways.";
RL   Oncogene 22:3307-3318(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 44-336.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 53-336, AND VARIANT VAL-136.
RC   TISSUE=Brain;
RX   PubMed=10574461; DOI=10.1093/dnares/6.5.329;
RA   Hirosawa M., Nagase T., Ishikawa K., Kikuno R., Nomura N., Ohara O.;
RT   "Characterization of cDNA clones selected by the GeneMark analysis
RT   from size-fractionated cDNA libraries from human brain.";
RL   DNA Res. 6:329-336(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 54-336, AND VARIANT VAL-136.
RC   TISSUE=Bone marrow, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH SLC11A2 AND WWP2.
RX   PubMed=18776082; DOI=10.1182/blood-2008-04-150953;
RA   Foot N.J., Dalton H.E., Shearwin-Whyatt L.M., Dorstyn L., Tan S.S.,
RA   Yang B., Kumar S.;
RT   "Regulation of the divalent metal ion transporter DMT1 and iron
RT   homeostasis by a ubiquitin-dependent mechanism involving Ndfips and
RT   WWP2.";
RL   Blood 112:4268-4275(2008).
RN   [8]
RP   FUNCTION, AND UBIQUITINATION.
RX   PubMed=19343052; DOI=10.1038/embor.2009.30;
RA   Mund T., Pelham H.R.;
RT   "Control of the activity of WW-HECT domain E3 ubiquitin ligases by
RT   NDFIP proteins.";
RL   EMBO Rep. 10:501-507(2009).
RN   [9]
RP   FUNCTION, INTERACTION WITH LYN; NDFIP1; NEDD4; PTEN AND SRC,
RP   SUBCELLULAR LOCATION, TOPOLOGY, PHOSPHORYLATION AT TYR-151; TYR-167;
RP   TYR-171 AND TYR-177, AND MUTAGENESIS OF 149-PRO--TYR-151; TYR-167;
RP   175-PRO--TYR-177 AND 184-PRO--TYR-186.
RX   PubMed=20534535; DOI=10.1073/pnas.0911714107;
RA   Mund T., Pelham H.R.;
RT   "Regulation of PTEN/Akt and MAP kinase signaling pathways by the
RT   ubiquitin ligase activators Ndfip1 and Ndfip2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010).
CC   -!- FUNCTION: Activates HECT domain-containing E3 ubiquitin-protein
CC       ligases, including ITCH, NEDD4, NEDD4L, SMURF2, WWP1 and WWP2, and
CC       consequently modulates the stability of their targets. As a
CC       result, may control many cellular processes. Recruits ITCH, NEDD4
CC       and SMURF2 to endosomal membranes. May modulate EGFR signaling.
CC       {ECO:0000269|PubMed:12761501, ECO:0000269|PubMed:19343052,
CC       ECO:0000269|PubMed:20534535}.
CC   -!- SUBUNIT: Forms heterodimers with NDFIP1. Interacts with HECT
CC       domain-containing E3 ubiquitin-protein ligases, including NEDD4.
CC       Interacts with NEDD4L (By similarity). Interacts with PTEN. When
CC       phosphorylated at Tyr-167, interacts with SRC and LYN SH2 domain.
CC       May thus act as a scaffold that recruits SRC to NDFIP1, enhancing
CC       NDFIP1 phosphorylation. Interacts with SLC11A2/DMT1. May interact
CC       with phosphorylated EGFR. {ECO:0000250,
CC       ECO:0000269|PubMed:12796489, ECO:0000269|PubMed:18776082,
CC       ECO:0000269|PubMed:20534535}.
CC   -!- SUBCELLULAR LOCATION: Endosome membrane
CC       {ECO:0000269|PubMed:18776082}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:18776082}. Golgi apparatus membrane
CC       {ECO:0000269|PubMed:12796489}. Endosome, multivesicular body
CC       membrane {ECO:0000250|UniProtKB:Q91ZP6}.
CC   -!- TISSUE SPECIFICITY: Expressed in brain, lung, heart, skeletal
CC       muscle, kidney, liver and placenta. {ECO:0000269|PubMed:12796489}.
CC   -!- INDUCTION: By T-cell activation. {ECO:0000269|PubMed:12796489}.
CC   -!- DOMAIN: The PY/WW-binding motifs are required for E3 ubiquitin-
CC       protein ligase activation and for ubiquitination.
CC   -!- PTM: Ubiquitinated by NEDD4 and ITCH. Also ubiquitinated by
CC       NEDD4L. Ubiquitination by NEDD4 or NEDD4L does not affect turnover
CC       (By similarity). {ECO:0000250}.
CC   -!- PTM: Undergoes transient tyrosine-phosphorylation following EGF
CC       stimulation, most probably catalyzed by SRC. Also phosphorylated
CC       by LYN and FYN. {ECO:0000269|PubMed:20534535}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH21988.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAH26126.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAA91863.1; Type=Erroneous initiation; Evidence={ECO:0000305};
DR   EMBL; AB097019; BAC77372.1; -; mRNA.
DR   EMBL; AB097028; BAC77381.1; -; mRNA.
DR   EMBL; AB097029; BAC77382.1; -; mRNA.
DR   EMBL; AB097030; BAC77383.1; -; mRNA.
DR   EMBL; AB097031; BAC77384.1; -; mRNA.
DR   EMBL; AL136442; CAH71782.1; -; Genomic_DNA.
DR   EMBL; AL355603; CAH71782.1; JOINED; Genomic_DNA.
DR   EMBL; AL355603; CAH73355.1; -; Genomic_DNA.
DR   EMBL; AL136442; CAH73355.1; JOINED; Genomic_DNA.
DR   EMBL; AK001723; BAA91863.1; ALT_INIT; mRNA.
DR   EMBL; AB032991; BAA86479.1; -; mRNA.
DR   EMBL; BC021988; AAH21988.1; ALT_INIT; mRNA.
DR   EMBL; BC026126; AAH26126.1; ALT_INIT; mRNA.
DR   CCDS; CCDS31998.1; -.
DR   RefSeq; NP_061953.2; NM_019080.2.
DR   UniGene; Hs.525093; -.
DR   ProteinModelPortal; Q9NV92; -.
DR   BioGrid; 120074; 17.
DR   IntAct; Q9NV92; 1.
DR   STRING; 9606.ENSP00000218652; -.
DR   iPTMnet; Q9NV92; -.
DR   PhosphoSitePlus; Q9NV92; -.
DR   BioMuta; NDFIP2; -.
DR   DMDM; 73921209; -.
DR   EPD; Q9NV92; -.
DR   MaxQB; Q9NV92; -.
DR   PaxDb; Q9NV92; -.
DR   PeptideAtlas; Q9NV92; -.
DR   PRIDE; Q9NV92; -.
DR   Ensembl; ENST00000218652; ENSP00000218652; ENSG00000102471.
DR   Ensembl; ENST00000612570; ENSP00000480798; ENSG00000102471.
DR   GeneID; 54602; -.
DR   KEGG; hsa:54602; -.
DR   UCSC; uc001vlf.4; human.
DR   CTD; 54602; -.
DR   DisGeNET; 54602; -.
DR   GeneCards; NDFIP2; -.
DR   HGNC; HGNC:18537; NDFIP2.
DR   HPA; HPA009160; -.
DR   MIM; 610041; gene.
DR   neXtProt; NX_Q9NV92; -.
DR   OpenTargets; ENSG00000102471; -.
DR   PharmGKB; PA134953250; -.
DR   eggNOG; KOG4812; Eukaryota.
DR   eggNOG; ENOG4111M6U; LUCA.
DR   GeneTree; ENSGT00390000012721; -.
DR   HOGENOM; HOG000038752; -.
DR   HOVERGEN; HBG057103; -.
DR   InParanoid; Q9NV92; -.
DR   OMA; SPPPYCS; -.
DR   OrthoDB; EOG091G0IMV; -.
DR   PhylomeDB; Q9NV92; -.
DR   TreeFam; TF324911; -.
DR   ChiTaRS; NDFIP2; human.
DR   GeneWiki; NDFIP2; -.
DR   GenomeRNAi; 54602; -.
DR   PRO; PR:Q9NV92; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   Bgee; ENSG00000102471; -.
DR   CleanEx; HS_NDFIP2; -.
DR   ExpressionAtlas; Q9NV92; baseline and differential.
DR   Genevisible; Q9NV92; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:BHF-UCL.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL.
DR   GO; GO:0032585; C:multivesicular body membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0004871; F:signal transducer activity; IMP:UniProtKB.
DR   GO; GO:0050699; F:WW domain binding; IPI:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0051224; P:negative regulation of protein transport; IMP:UniProtKB.
DR   GO; GO:0032410; P:negative regulation of transporter activity; IMP:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IMP:UniProtKB.
PE   1: Evidence at protein level;
KW   Complete proteome; Endosome; Golgi apparatus; Membrane;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   CHAIN         1    336       NEDD4 family-interacting protein 2.
FT                                /FTId=PRO_0000096794.
FT   TOPO_DOM      1    231       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    232    252       Helical. {ECO:0000255}.
FT   TOPO_DOM    253    257       Extracellular. {ECO:0000255}.
FT   TRANSMEM    258    278       Helical. {ECO:0000255}.
FT   TOPO_DOM    279    287       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    288    308       Helical. {ECO:0000255}.
FT   TOPO_DOM    309    336       Extracellular. {ECO:0000255}.
FT   REGION      148    151       Interaction with NEDD4. {ECO:0000250}.
FT   MOTIF       149    151       WW-binding 1.
FT   MOTIF       175    177       WW-binding 2.
FT   MOTIF       184    186       WW-binding 3.
FT   SITE        186    186       Not phosphorylated by SRC.
FT   MOD_RES     151    151       Phosphotyrosine; by SRC; dependent on Y-
FT                                167. {ECO:0000269|PubMed:20534535}.
FT   MOD_RES     167    167       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:20534535}.
FT   MOD_RES     171    171       Phosphotyrosine; by SRC; dependent on Y-
FT                                167. {ECO:0000269|PubMed:20534535}.
FT   MOD_RES     177    177       Phosphotyrosine; by SRC; dependent on Y-
FT                                167. {ECO:0000269|PubMed:20534535}.
FT   VARIANT     124    124       P -> S (in dbSNP:rs55887763).
FT                                /FTId=VAR_061687.
FT   VARIANT     136    136       A -> V (in dbSNP:rs11549502).
FT                                {ECO:0000269|PubMed:10574461,
FT                                ECO:0000269|PubMed:12761501,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_023414.
FT   MUTAGEN     150    151       PY->AG: Loss of E3 ubiquitin-protein
FT                                ligase activation; when associated with
FT                                175-P--G-177 AND 184-P--G-186. Greatly
FT                                decreases NEDD4-binding; when associated
FT                                with 175-P--G-177 and 184-P--G-186. No
FT                                effect on PTEN-binding; when associated
FT                                with 175-P--G-177 AND 184-P--G-186.
FT   MUTAGEN     167    167       Y->F: Loss of NDFIP2 phosphorylation by
FT                                SRC. {ECO:0000269|PubMed:20534535}.
FT   MUTAGEN     176    177       PY->AG: Loss of E3 ubiquitin-protein
FT                                ligase activation; when associated with
FT                                149-P--G-151 AND 184-P--G-186. Greatly
FT                                decreases NEDD4-binding; when associated
FT                                with 149-P-G-151 AND 184-P--G-186. No
FT                                effect on PTEN-binding; when associated
FT                                with 149-P--G-151 AND 184-P--G-186.
FT   MUTAGEN     185    186       TY->AG: Loss of E3 ubiquitin-protein
FT                                ligase activation; when associated with
FT                                149-P--G-151 AND 175-P--G-177. Greatly
FT                                decreases NEDD4-binding; when associated
FT                                with 149-P--G-151 AND 175-P--G-177. No
FT                                effect on PTEN-binding; when associated
FT                                with 149-P--G-151 AND 175-P--G-177.
SQ   SEQUENCE   336 AA;  36390 MW;  A7E386C12886321E CRC64;
     MARRRSQRVC ASGPSMLNSA RGAPELLRGT ATNAEVSAAA AGATGSEELP PGDRGCRNGG
     GRGPAATTSS TGVAVGAEHG EDSLSRKPDP EPGRMDHHQP GTGRYQVLLN EEDNSESSAI
     EQPPTSNPAP QIVQAASSAP ALETDSSPPP YSSITVEVPT TSDTEVYGEF YPVPPPYSVA
     TSLPTYDEAE KAKAAAMAAA AAETSQRIQE EECPPRDDFS DADQLRVGND GIFMLAFFMA
     FIFNWLGFCL SFCITNTIAG RYGAICGFGL SLIKWILIVR FSDYFTGYFN GQYWLWWIFL
     VLGLLLFFRG FVNYLKVRNM SESMAAAHRT RYFFLL
//